Skip to main content
KANGSTEM BIOTECH CO., LTD. logo

KANGSTEM BIOTECH CO., LTD. — Investor Relations & Filings

Ticker · 217730 ISIN · KR7217730001 KO Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2019-10-24 Investor Presentation
Country KR South Korea
Listing KO 217730

About KANGSTEM BIOTECH CO., LTD.

https://kangstem.com

KANGSTEM BIOTECH CO., LTD. is a biopharmaceutical company that researches and develops advanced stem cell therapies. The company focuses on creating treatments for rare, incurable, and autoimmune diseases, with a pipeline that includes therapeutic candidates for neurological disorders. Leveraging proprietary technologies for the isolation and mass culture of mesenchymal stem cells, Kangstem Biotech also develops and commercializes stem cell culture media and related cosmetic products. The company is dedicated to addressing unmet medical needs through the development of next-generation biopharmaceuticals.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Investor Presentation Classification · 98% confidence The document is a formal announcement regarding the scheduling and purpose of an Investor Relations (IR) event (기업설명회). It provides details such as the date, location, target audience, and the specific topic (clinical trial results). Since this is a short announcement notifying the public about an upcoming event rather than the presentation materials themselves, it falls under the category of a regulatory filing announcement regarding an event.
2019-10-24 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and major contracts (such as collateral agreements) of a major shareholder (Kang Kyung-sun) in the company 'Kangstem Biotech'. This type of filing is specifically used to notify the market of significant changes in share ownership and control, which falls under the 'Major Shareholding Notification' category.
2019-10-08 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, including major shareholding notifications, director dealings, and collateral agreements. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2019-09-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea (often referred to as a 'Section 16' equivalent in the US) to report insider transactions, including changes in share ownership by directors or major shareholders. Based on the provided filing categories, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions and ownership changes by company directors and executives.
2019-09-09 Korean
최대주주변경을수반하는주식담보제공계약체결
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory filing from a Korean company (Kangstem Biotech) detailing a 'Contract for Stock Collateralization Involving a Change in the Largest Shareholder'. This type of disclosure, which reports on the pledging of shares by a major shareholder as collateral for debt, falls under the category of capital and financing updates, as it relates to the company's capital structure and significant financial obligations of its major shareholder. It does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Major Shareholding Notification' (which is for threshold changes), making 'CAP' the most accurate classification.
2019-09-06 Korean
반기보고서 (2019.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company '강스템바이오텍' covering the period from January 1, 2019, to June 30, 2019. It contains detailed financial information, business overviews, capital structure, and management discussions, which are characteristic of an interim financial report. It is not a mere announcement or certification, but the full report itself. H1 2019
2019-08-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.